Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for genetic manipulation. In this review, we discuss the current development of CRISPR/Cas9 technologies for therapeutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. Different methods used to facilitate efficient CRISPR delivery and gene editing in T cells are compared. The potential of genetic manipulation using CRISPR/Cas9 system to generate universal CAR T cells and potent T cells that are resistant to exhaustion and inhibition is explored. We also address the safety concerns associated with the use of CRISPR/Cas9 gene editing and provide potential solutions and future directions of CRISPR application in the field of CAR T cell immunotherapy. As an integration-free gene insertion method, CRISPR/Cas9 holds great promise as an efficient gene knock-in platform. Given the tremendous progress that has been made in the past few years, we believe that the CRISPR/Cas9 technology holds immense promise for advancing immunotherapy.

Key words： CRISPR/Cas9; chimeric antigen receptor; T lymphocytes; adoptive immunotherapy; gene therapy

References

1 AuerTO, DuroureK, De CianA, ConcordetJP, Del BeneF (2014) Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res24:142–153

2 BarrangouR, FremauxC, DeveauH, RichardsM, BoyavalP, MoineauS, RomeroDA, HorvathP (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science315:1709–1712

3 BibikovaM, GolicM, GolicKG, CarrollD (2002) Targeted chromosomal cleavage and mutagenesis in Drosophilausing zinc-finger nucleases. Genetics161:1169–1175

4 BibikovaM, BeumerK, TrautmanJK, CarrollD (2003) Enhancing gene targeting with designed zinc finger nucleases. Science300:764

5 BochJ, ScholzeH, SchornackS, LandgrafA, HahnS, KayS, LahayeT, NickstadtA, BonasU (2009) Breaking the code of DNA binding specificity of TAL-type III effectors. Science326:1509–1512

6 BrentjensRJ, LatoucheJB, SantosE, MartiF, GongMC, LyddaneC, KingPD, LarsonS, WeissM, RiviereI (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med9:279–286

7 BriggsAW, RiosX, ChariR, YangL, ZhangF, MaliP, ChurchGM (2012) Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers. Nucleic Acids Res40:e117

8 CarpenitoC, MiloneMC, HassanR, SimonetJC, LakhalM, SuhoskiMM, Varela-RohenaA, HainesKM, HeitjanDF, AlbeldaSM (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA106:3360–3365

9 CermakT, DoyleEL, ChristianM, WangL, ZhangY, SchmidtC, BallerJA, SomiaNV, BogdanoveAJ, VoytasDF (2011) Efficient design and assembly of custom TALEN and other TAL effectorbased constructs for DNA targeting. Nucleic Acids Res39:e82

10 ChavezA, ScheimanJ, VoraS, PruittBW, TuttleM, IyerPRE, LinS, KianiS, GuzmanCD, WiegandDJ (2015) Highly efficient Cas9-mediated transcriptional programming. Nat Methods12:326–328

11 ChengAW, WangH, YangH, ShiL, KatzY, TheunissenTW, RangarajanS, ShivalilaCS, DadonDB, JaenischR (2013) Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res23:1163–1171

12 ChiS, WeissA, WangH (2016) A CRISPR-based toolbox for studying Tcell signal transduction. Biomed Res Int2016:5052369

13 ChoSW, KimS, KimY, KweonJ, KimHS, BaeS, KimJS (2014) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res24:132–141

14 CongL, RanFA, CoxD, LinS, BarrettoR, HabibN, HsuPD, WuX, JiangW, MarraffiniLA (2013) Multiplex genome engineering using CRISPR/Cas systems. Science339:819–823

15 CrosettoN, MitraA, SilvaMJ, BienkoM, DojerN, WangQ, KaracaE, ChiarleR, SkrzypczakM, GinalskiK (2013) Nucleotideresolution DNA double-strand break mapping by next-generation sequencing. Nat Methods10:361–365

16 CyranoskiD (2016) CRISPR gene-editing tested in a person for the first time. Nature539:479

17 DeltchevaE, ChylinskiK, SharmaCM, GonzalesK, ChaoY, PirzadaZA, EckertMR, VogelJ, CharpentierE (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature471:602–607

18 DiCarloJE, NorvilleJE, MaliP, RiosX, AachJ, ChurchGM (2013) Genome engineering in Saccharomyces cerevisiaeusing CRISPR-Cas systems. Nucleic Acids Res41:4336–4343

19 DoyonY, McCammonJM, MillerJC, FarajiF, NgoC, KatibahGE, AmoraR, HockingTD, ZhangL, RebarEJ (2008) Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol26:702–708

20 EyquemJ, Mansilla-SotoJ, GiavridisT, van der StegenSJ, HamiehM, CunananKM, OdakA, GonenM, SadelainM (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature543:113–117

21 FriedlandAE, BaralR, SinghalP, LoveluckK, ShenS, SanchezM, MarcoE, GottaGM, MaederML, KennedyEM (2015) Characterization of Staphylococcus aureusCas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol16:257

22 FrockRL, HuJ, MeyersRM, HoYJ, KiiE, AltFW (2015) Genomewide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol33:179–186

23 FuY, FodenJA, KhayterC, MaederML, ReyonD, JoungJK, SanderJD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol31:822–826

24 FuY, SanderJD, ReyonD, CascioVM, JoungJK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol32:279–284

25 GasiunasG, BarrangouR, HorvathP, SiksnysV (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA109: E2579–2586

26 GilbertLA, LarsonMH, MorsutL, LiuZ, BrarGA, TorresSE, Stern-GinossarN, BrandmanO, WhiteheadEH, DoudnaJA (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell154:442–451

27 GonzalezF, ZhuZ, ShiZD, LelliK, VermaN, LiQV, HuangfuD (2014) An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell15:215–226

28 GrossG, WaksT, EshharZ (1989) Expression of immunoglobulin-Tcell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA86:10024–10028

29 GuilingerJP, ThompsonDB, LiuDR (2014) Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol32:577–582

30 HeX, TanC, WangF, WangY, ZhouR, CuiD, YouW, ZhaoH, RenJ, FengB (2016) Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res44:e85

31 HendelA, BakRO, ClarkJT, KennedyAB, RyanDE, RoyS, SteinfeldI, LunstadBD, KaiserRJ, WilkensAB (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol33:985–989

32 HiltonIB, D’IppolitoAM, VockleyCM, ThakorePI, CrawfordGE, ReddyTE, GersbachCA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol33:510–517

33 HoosA (2016) Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov15:235–247

34 HorvathP, BarrangouR (2010) CRISPR/Cas, the immune system of bacteria and archaea. Science327:167–170

35 HouP, ChenS, WangS, YuX, ChenY, JiangM, ZhuangK, HoW, HouW, HuangJ (2015) Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep5:15577

36 HsuPD, ScottDA, WeinsteinJA, RanFA, KonermannS, AgarwalaV, LiY, FineEJ, WuX, ShalemO (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol31:827–832

37 HuW, KaminskiR, YangF, ZhangY, CosentinoL, LiF, LuoB, Alvarez-CarbonellD, Garcia-MesaY, KarnJ (2014) RNAdirected gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA111:11461–11466

38 HwangWY, FuY, ReyonD, MaederML, TsaiSQ, SanderJD, PetersonRT, YehJR, JoungJK (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol31:227–229

39 IrvingBA, WeissA (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell64:891–901

40 JinekM, ChylinskiK, FonfaraI, HauerM, DoudnaJA, CharpentierE (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science337:816–821

41 KalosM, JuneCH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity39:49–60

42 KearnsNA, PhamH, TabakB, GengaRM, SilversteinNJ, GarberM, MaehrR (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods12:401–403

43 KimHJ, LeeHJ, KimH, ChoSW, KimJS (2009) Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res19:1279–1288

44 KimS, KimD, ChoSW, KimJ, KimJS (2014) Highly efficient RNAguided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res24:1012–1019

45 KimD, BaeS, ParkJ, KimE, KimS, YuHR, HwangJ, KimJI, KimJS (2015). Digenome-seq: genome-wide profiling of CRISPRCas9 off-target effects in human cells. Nat Methods12:237–243, 231–243

46 KonermannS, BrighamMD, TrevinoAE, JoungJ, AbudayyehOO, BarcenaC, HsuPD, HabibN, GootenbergJS, NishimasuH (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature517:583–588

47 LiJF, NorvilleJE, AachJ, McCormackM, ZhangD, BushJ, ChurchGM, SheenJ (2013) Multiplex and homologous recombinationmediated genome editing in Arabidopsis and Nicotiana benthamianausing guide RNA and Cas9. Nat Biotechnol31:688–691

48 LiC, GuanX, DuT, JinW, WuB, LiuY, WangP, HuB, GriffinGE, ShattockRJ (2015) Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirusdelivered CRISPR/Cas9. J Gen Virol96:2381–2393

49 LiuX, ZhangY, ChengC, ChengAW, ZhangX, LiN, XiaC, WeiX, LiuX, WangH (2017) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res27:154–157

50 LloydA, VickeryON, LaugelB (2013) Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol4:221

51 LongC, McAnallyJR, SheltonJM, MireaultAA, Bassel-DubyR, OlsonEN (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science345:1184–1188

52 MaederML, LinderSJ, CascioVM, FuY, HoQH, JoungJK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods10:977–979

53 MaherJ, BrentjensRJ, GunsetG, RiviereI, SadelainM(2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol20:70–75

54 MakarovaKS, GrishinNV, ShabalinaSA, WolfYI, KooninEV (2006) A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct1:7

55 MaliP, AachJ, StrangesPB, EsveltKM, MoosburnerM, KosuriS, YangL, ChurchGM (2013a) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol31:833–838

56 MaliP, YangL, EsveltKM, AachJ, GuellM, DiCarloJE, NorvilleJE, ChurchGM (2013b) RNA-guided human genome engineering via Cas9. Science339:823–826

57 MandalPK, FerreiraLM, CollinsR, MeissnerTB, BoutwellCL, FriesenM, VrbanacV, GarrisonBS, StortchevoiA, BryderD (2014) Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell15:643–652

58 MausMV, GruppSA, PorterDL, JuneCH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood123:2625–2635

59 MillerJC, TanS, QiaoG, BarlowKA, WangJ, XiaDF, MengX, PaschonDE, LeungE, HinkleySJ (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol29:143–148

60 MortonJ, DavisMW, JorgensenEM, CarrollD (2006) Induction and repair of zinc-finger nuclease-targeted double-strand breaks in Caenorhabditis elegans somatic cells. Proc Natl Acad Sci USA103:16370–16375

61 MoscouMJ, BogdanoveAJ (2009) A simple cipher governs DNA recognition by TAL effectors. Science326:1501

62 NakadeS, TsubotaT, SakaneY, KumeS, SakamotoN, ObaraM, DaimonT, SezutsuH, YamamotoT, SakumaT (2014)Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat Commun5:5560

63 NekrasovV, StaskawiczB, WeigelD, JonesJD, KamounS (2013) Targeted mutagenesis in the model plant Nicotiana benthamianausing Cas9 RNA-guided endonuclease. Nat Biotechnol31:691–693

64 PavletichNP, PaboCO (1991) Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science252:809–817

65 PerezEE, WangJ, MillerJC, JouvenotY, KimKA, LiuO, WangN, LeeG, BartsevichVV, LeeYL (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol26:808–816

66 Perez-PineraP, KocakDD, VockleyCM, AdlerAF, KabadiAM, PolsteinLR, ThakorePI, GlassKA, OusteroutDG, LeongKW (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods10:973–976

67 PoirotL, PhilipB, Schiffer-ManniouiC, Le ClerreD, Chion-SotinelI, DerniameS, PotrelP, BasC, LemaireL, GalettoR (2015) Multiplex genome-edited T-cell manufacturing platform for “Offthe-Shelf” adoptive T-cell immunotherapies. Cancer Res75:3853–3864

68 PorteusMH, BaltimoreD (2003) Chimeric nucleases stimulate gene targeting in human cells. Science300:763

69 ProvasiE, GenoveseP, LombardoA, MagnaniZ, LiuPQ, ReikA, ChuV, PaschonDE, ZhangL, KuballJ (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med18:807–815

70 QiLS, LarsonMH, GilbertLA, DoudnaJA, WeissmanJS, ArkinAP, LimWA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell152:1173–1183

71 RanFA, HsuPD, LinCY, GootenbergJS, KonermannS, TrevinoAE, ScottDA, InoueA, MatobaS, ZhangY (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell154:1380–1389

72 RanFA, CongL, YanWX, ScottDA, GootenbergJS, KrizAJ, ZetscheB, ShalemO, WuX, MakarovaKS (2015) In vivo genome editing using Staphylococcus aureusCas9. Nature520:186–191

73 RenJ, LiuX, FangC, JiangS, JuneCH, ZhaoY (2016) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res16:1300

74 RenJ, ZhangX, LiuX, FangC, JiangS, JuneCH, ZhaoY (2017) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget8:17002–17011

75 SadelainM, PapapetrouEP, BushmanFD (2011) Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer12:51–58

76 SakumaT, TakenagaM, KawabeY, NakamuraT, KamihiraM, YamamotoT (2015) Homologous recombination-independent large gene cassette knock-in in CHO cells using TALEN and MMEJ-directed donor plasmids. Int J Mol Sci16:23849–23866

77 SatherBD, Romano IbarraGS, SommerK, CuringaG, HaleM, KhanIF, SinghS, SongY, GwiazdaK, SahniJ (2015) Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med7:307ra156

78 SchumannK, LinS, BoyerE, SimeonovDR, SubramaniamM, GateRE, HaliburtonGE, YeCJ, BluestoneJA, DoudnaJA (2015) Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA112:10437–10442

79 SchwankG, KooBK, SasselliV, DekkersJF, HeoI, DemircanT, SasakiN, BoymansS, CuppenE, van der EntCK (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell13:653–658

80 ShalemO, SanjanaNE, HartenianE, ShiX, ScottDA, MikkelsenTS, HecklD, EbertBL, RootDE, DoenchJG (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science343:84–87

81 ShenB, ZhangJ, WuH, WangJ, MaK, LiZ, ZhangX, ZhangP, HuangX (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res23:720–723

82 SlaymakerIM, GaoL, ZetscheB, ScottDA, YanWX, ZhangF (2016) Rationally engineered Cas9 nucleases with improved specificity. Science351:84–88

83 SuS, HuB, ShaoJ, ShenB, DuJ, DuY, ZhouJ, YuL, ZhangL, ChenF (2016) CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep6:20070

84 SuzukiK, TsunekawaY, Hernandez-BenitezR, WuJ, ZhuJ, KimEJ, HatanakaF, YamamotoM, AraokaT, LiZ (2016) In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature540:144–149

85 SwiechL, HeidenreichM, BanerjeeA, HabibN, LiY, TrombettaJ, SurM, ZhangF (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol33:102–106

86 TanenbaumME, GilbertLA, QiLS, WeissmanJS, ValeRD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell159:635–646

87 TebasP, SteinD, TangWW, FrankI, WangSQ, LeeG, SprattSK, SuroskyRT, GiedlinMA, NicholG (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med370:901–910

88 TorikaiH, ReikA, LiuPQ, ZhouY, ZhangL, MaitiS, HulsH, MillerJC, KebriaeiP, RabinovichB (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood119:5697–5705

89 TownsendJA, WrightDA, WinfreyRJ, FuF, MaederML, JoungJK, VoytasDF (2009) High-frequency modification of plant genes using engineered zinc-finger nucleases. Nature459:442–445

90 TsaiSQ, ZhengZ, NguyenNT, LiebersM, TopkarVV, ThaparV, WyvekensN, KhayterC, IafrateAJ, LeLP (2015) GUIDEseq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol33:187–197

91 UrnovFD, MillerJC, LeeYL, BeausejourCM, RockJM, AugustusS, JamiesonAC, PorteusMH, GregoryPD, HolmesMC (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature435:646–651

92 WangH, YangH, ShivalilaCS, DawlatyMM, ChengAW, ZhangF, JaenischR (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell153:910–918

93 WangW, YeC, LiuJ, ZhangD, KimataJT, ZhouP (2014) CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE9:e115987

94 WiedenheftB, SternbergSH, DoudnaJA (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature482:331–338

95 WilliamsMR, Fricano-KuglerCJ, GetzSA, SkeltonPD, LeeJ, RizzutoCP, GellerJS, LiM, LuikartBW (2016) A retroviral CRISPR-Cas9 system for cellular autism-associated phenotype discovery in developing neurons. Sci Rep6:25611

96 WyvekensN, TopkarVV, KhayterC, JoungJK, TsaiSQ (2015) Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing. Hum Gene Ther26:425–431

97 YeL, WangJ, BeyerAI, TequeF, CradickTJ, QiZ, ChangJC, BaoG, MuenchMO, YuJ(2014) Seamless modification of wildtype induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA111:9591–9596

98 YinH, XueW, ChenS, BogoradRL, BenedettiE, GrompeM, KotelianskyV, SharpPA, JacksT, AndersonDG (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol32:551–553

99 ZhenS, HuaL, LiuYH, GaoLC, FuJ, WanDY, DongLH, SongHF, GaoX (2015) Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther22:404–412